GNTA
Genenta Science S.p.A.
Price Chart
Latest Quote
$1.55
+0.11 (+7.64%)
Current Price
| Previous Close | $1.44 |
| Open | $1.48 |
| Day High | $1.63 |
| Day Low | $1.44 |
| Volume | 98,650 |
Stock Information
Note: Financial values converted from EUR to USD
| Shares Outstanding | 48.22M |
| Total Debt | $8.70M |
| Cash Equivalents | $32.22M |
| Net Income | $-7.47M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $74.74M |
| EPS (TTM) | $-0.40 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $16.02M |
| Income | $-7.47M |
| Book/sh | $1.07 |
| Cash/sh | $0.58 |
| Employees | 9 |
Financial Ratios
| Quick Ratio | 13.90 |
| Current Ratio | 14.15 |
| Debt/Eq | 34.81 |
Returns & Margins
| ROA | -17.67% |
| ROE | -38.03% |
Ownership
| Insider Ownership | 42.47% |
| Institutional Ownership | 7.38% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.38 |
| P/B | 1.45 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $1.65 |
| SMA50 | $1.37 |
| SMA200 | $1.51 |
| RSI | 38.98 |
| ATR | 0.1402 |
| Shares Float | 13.87M |
| Short Float | 0.36% |
| Short Ratio | 0.04 |
| Volatility | 0.75 |
| Rel Volume | 0.48 |
Performance History
| Week | +3.33% |
| Month | -17.11% |
| Quarter | +114.38% |
| 6 Months | +13.14% |
| YTD | +9.93% |
| Year | -59.74% |
| 3 Years | -73.95% |
| 10 Years | -85.91% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $1.55 | 98,800 |
| 2026-07-16 | $1.44 | 92,700 |
| 2026-07-15 | $1.50 | 237,300 |
| 2026-07-14 | $1.25 | 75,700 |
| 2026-07-13 | $1.32 | 95,400 |
| 2026-07-10 | $1.50 | 41,500 |
| 2026-07-09 | $1.59 | 54,800 |
| 2026-07-08 | $1.53 | 57,200 |
| 2026-07-07 | $1.61 | 78,800 |
| 2026-07-06 | $1.68 | 103,800 |
| 2026-07-02 | $1.72 | 91,900 |
| 2026-07-01 | $1.75 | 144,800 |
| 2026-06-30 | $1.84 | 158,000 |
| 2026-06-29 | $1.80 | 262,700 |
| 2026-06-26 | $1.81 | 162,000 |
| 2026-06-25 | $1.73 | 236,900 |
| 2026-06-24 | $1.85 | 254,300 |
| 2026-06-23 | $1.84 | 232,500 |
| 2026-06-22 | $1.92 | 1,489,200 |
| 2026-06-18 | $1.68 | 138,500 |
About Genenta Science S.p.A.
Genenta Science S.p.A., a clinical-stage biotechnology company, develops hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company offers Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is developing Temferon for use in the treatment of other solid tumor indications. In addition, the company develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.
đ° Latest News
European Equities Traded in the US as American Depositary Receipts Decline Friday
MT Newswires âĸ 2026-07-17T14:57:57ZEuropean Equities Traded in the US as American Depositary Receipts Higher Tuesday
MT Newswires âĸ 2026-03-17T15:18:34ZGenenta Science SPA (GNTA) Shifting from Biotech to Defense Business
Insider Monkey âĸ 2026-02-28T00:53:10Z
European Equities Traded in the US as American Depositary Receipts Gain Friday
MT Newswires âĸ 2026-01-02T16:09:33ZUS-China Trade Optimism Lifts US Equity Futures Pre-Bell
MT Newswires âĸ 2025-10-27T13:00:09ZGenenta Science (GNTA): Assessing Valuation After Expanded Anemocyte Partnership Spurs Industry Optimism
Simply Wall St. âĸ 2025-10-27T09:07:34Z
Genenta Science And 2 Other Penny Stocks To Consider
Simply Wall St. âĸ 2025-10-14T18:05:12Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $7,553,174 | $11,168,145 | $13,419,812 | $12,631,810 |
| Other Income Expense | $-611,455 | $881,477 | $-253,650 | $2,892,879 |
| Other Non Operating Income Expenses | $13,103 | $605,837 | $-5,576 | $277,426 |
| Net Non Operating Interest Income Expense | $695,994 | $92,806 | $353,715 | $42,302 |
| Operating Expense | $7,553,174 | $11,168,145 | $13,419,812 | $12,631,810 |
| General And Administrative Expense | $4,465,741 | $5,663,337 | $6,014,527 | $6,525,254 |
| Total Other Finance Cost | - | - | $-353,715 | $-42,302 |
| Interest Expense | - | - | - | - |
| Interest Expense Non Operating | - | - | - | - |
| Other Operating Expenses | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-7,468,634 | $-10,193,863 | $-13,319,747 | $-9,696,629 |
| Net Interest Income | $695,994 | $92,806 | $353,715 | $42,302 |
| Interest Income | $695,994 | $92,806 | $353,715 | $42,302 |
| Normalized Income | $-6,844,076 | $-10,469,503 | $-13,071,673 | $-12,312,081 |
| Net Income From Continuing And Discontinued Operation | $-7,468,634 | $-10,193,863 | $-13,319,747 | $-9,696,629 |
| Total Operating Income As Reported | $-7,553,174 | $-11,168,145 | $-13,419,812 | $-12,631,810 |
| Net Income Common Stockholders | $-7,468,634 | $-10,193,863 | $-13,319,747 | $-9,696,629 |
| Net Income | $-7,468,634 | $-10,193,863 | $-13,319,747 | $-9,696,629 |
| Net Income Including Noncontrolling Interests | $-7,468,634 | $-10,193,863 | $-13,319,747 | $-9,696,629 |
| Net Income Continuous Operations | $-7,468,634 | $-10,193,863 | $-13,319,747 | $-9,696,629 |
| Pretax Income | $-7,468,634 | $-10,193,863 | $-13,319,747 | $-9,696,629 |
| Interest Income Non Operating | $695,994 | $92,806 | $353,715 | $42,302 |
| Operating Income | $-7,553,174 | $-11,168,145 | $-13,419,812 | $-12,631,810 |
| Per Share | ||||
| Diluted EPS | $-0.38 | $-0.56 | $-0.73 | $-0.54 |
| Basic EPS | $-0.38 | $-0.56 | $-0.73 | $-0.54 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-6,896,496 | $-11,392,861 | $-13,123,181 | $-15,240,239 |
| Total Unusual Items | $-624,558 | $275,640 | $-248,074 | $2,615,452 |
| Total Unusual Items Excluding Goodwill | $-624,558 | $275,640 | $-248,074 | $2,615,452 |
| Reconciled Depreciation | $32,119 | $50,924 | $48,557 | $7,023 |
| EBITDA (Bullshit earnings) | $-7,521,054 | $-11,117,221 | $-13,371,255 | $-12,624,787 |
| EBIT | $-7,553,174 | $-11,168,145 | $-13,419,812 | $-12,631,810 |
| Diluted Average Shares | $22,543,962 | $20,900,708 | $20,835,990 | $20,835,934 |
| Basic Average Shares | $22,543,962 | $20,900,708 | $20,835,990 | $20,835,934 |
| Diluted NI Availto Com Stockholders | $-7,468,634 | $-10,193,863 | $-13,319,747 | $-9,696,629 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Gain On Sale Of Security | $-624,558 | $275,640 | $-248,074 | $2,615,452 |
| Research And Development | $3,087,432 | $5,504,808 | $7,405,285 | $6,106,556 |
| Selling General And Administration | $4,465,741 | $5,663,337 | $6,014,527 | $6,525,254 |
| Other Gand A | $2,175,092 | $2,807,909 | $3,089,584 | $2,156,776 |
| Insurance And Claims | $23,809 | $20,751 | $25,061 | $1,437,158 |
| Salaries And Wages | $2,266,841 | $2,834,677 | $2,899,882 | $2,931,321 |
Fetched: 2026-07-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $24,980,715 | $14,292,240 | $23,369,845 | $35,614,966 |
| Total Assets | $36,474,103 | $16,955,270 | $25,560,041 | $38,245,291 |
| Total Non Current Assets | $2,184,328 | $401,482 | $1,247,726 | $1,963,276 |
| Other Non Current Assets | $5,156 | $20,524 | $240,842 | $48,529 |
| Non Current Accounts Receivable | $2,153,477 | $331,865 | $911,978 | $1,787,057 |
| Current Assets | $34,289,775 | $16,553,787 | $24,312,315 | $36,282,016 |
| Other Current Assets | $385,952 | $241,141 | $73,961 | $250,944 |
| Prepaid Assets | $237,097 | $176,124 | $471,527 | $165,491 |
| Receivables | $1,470,468 | $1,656,652 | $2,291,701 | $1,787,056 |
| Taxes Receivable | $1,470,468 | $1,656,652 | $2,291,701 | $1,787,056 |
| Cash Cash Equivalents And Short Term Investments | $32,196,258 | $14,479,870 | $21,475,126 | $34,078,525 |
| Cash And Cash Equivalents | $6,322,397 | $5,240,477 | $4,222,143 | $34,078,525 |
| Cash Financial | $6,322,397 | $5,240,477 | $4,222,143 | $34,078,525 |
| Current Deferred Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $2,373,702 | - | - | - |
| Total Debt | $8,696,099 | - | - | - |
| Long Term Debt And Capital Lease Obligation | $8,696,099 | - | - | - |
| Long Term Debt | $8,696,099 | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $11,493,388 | $2,663,030 | $2,190,195 | $2,630,326 |
| Total Non Current Liabilities Net Minority Interest | $9,071,011 | $261,838 | $205,020 | $132,885 |
| Current Liabilities | $2,422,378 | $2,401,192 | $1,985,175 | $2,497,441 |
| Other Current Liabilities | $136,109 | $386,325 | $291,733 | $340,701 |
| Payables And Accrued Expenses | $2,286,269 | $2,014,867 | $1,693,443 | $2,156,740 |
| Payables | $2,069,764 | $569,537 | $532,841 | $1,365,712 |
| Accounts Payable | $1,726,257 | $363,525 | $337,384 | $1,191,872 |
| Other Non Current Liabilities | - | $1,324 | $16,692 | $31,131 |
| Equity | ||||
| Common Stock Equity | $24,980,715 | $14,292,240 | $23,369,845 | $35,614,966 |
| Total Equity Gross Minority Interest | $24,980,715 | $14,292,240 | $23,369,845 | $35,614,966 |
| Stockholders Equity | $24,980,715 | $14,292,240 | $23,369,845 | $35,614,966 |
| Gains Losses Not Affecting Retained Earnings | $190,451 | $101,734 | $264,374 | $0 |
| Other Equity Adjustments | $190,451 | $101,734 | $264,374 | - |
| Retained Earnings | $-71,583,374 | $-64,114,740 | $-53,920,877 | $-40,564,517 |
| Other | ||||
| Ordinary Shares Number | $26,801,077 | $20,919,438 | $20,836,048 | $20,835,934 |
| Share Issued | $26,801,077 | $20,919,438 | $20,836,048 | $20,835,934 |
| Tangible Book Value | $24,980,715 | $14,292,240 | $23,369,845 | $35,614,966 |
| Invested Capital | $33,676,814 | $14,292,240 | $23,369,845 | $35,614,966 |
| Working Capital | $31,867,397 | $14,152,596 | $22,327,139 | $33,784,574 |
| Total Capitalization | $33,676,814 | $14,292,240 | $23,369,845 | $35,614,966 |
| Capital Stock | $96,373,638 | $78,305,246 | $77,026,348 | $76,179,482 |
| Common Stock | $96,373,638 | $78,305,246 | $77,026,348 | $76,179,482 |
| Employee Benefits | $374,911 | $260,514 | $188,328 | $101,753 |
| Non Current Pension And Other Postretirement Benefit Plans | $374,911 | $260,514 | $188,328 | $101,753 |
| Current Accrued Expenses | $216,505 | $1,445,330 | $1,160,602 | $791,028 |
| Dueto Related Parties Current | $343,507 | $206,012 | $195,457 | $173,840 |
| Net PPE | $25,695 | $49,093 | $94,907 | $127,690 |
| Accumulated Depreciation | $-144,579 | $-112,459 | $-61,534 | $-13,890 |
| Gross PPE | $170,273 | $161,552 | $156,441 | $141,580 |
| Other Properties | $69,850 | $61,129 | $56,017 | - |
| Machinery Furniture Equipment | $100,423 | $100,423 | $100,423 | $141,580 |
| Other Short Term Investments | $25,873,861 | $9,239,393 | $17,252,983 | $0 |
| Additional Paid In Capital | - | - | $0 | $0 |
Fetched: 2026-07-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-7,864,101 | $-7,142,447 | $-12,831,766 | $-8,515,733 |
| Operating Activities | ||||
| Operating Cash Flow | $-7,855,380 | $-7,137,337 | $-12,815,993 | $-8,484,771 |
| Cash Flow From Continuing Operating Activities | $-7,855,380 | $-7,137,337 | $-12,815,993 | $-8,484,771 |
| Operating Gains Losses | $114,398 | $72,186 | $86,574 | $103,346 |
| Investing Activities | ||||
| Capital Expenditure | $-8,721 | $-5,110 | $-15,774 | $-30,962 |
| Investing Cash Flow | $-16,634,948 | $7,872,657 | $-17,033,816 | $-30,962 |
| Cash Flow From Continuing Investing Activities | $-16,634,948 | $7,872,657 | $-17,033,816 | $-30,962 |
| Financing Activities | ||||
| Financing Cash Flow | $25,491,773 | $309,831 | $607 | $0 |
| Cash Flow From Continuing Financing Activities | $25,491,773 | $309,831 | $607 | $0 |
| Net Other Financing Charges | $16,913,482 | $309,831 | $607 | - |
| Issuance Of Capital Stock | - | - | $607 | $0 |
| Net Common Stock Issuance | - | - | $607 | $0 |
| Common Stock Issuance | - | - | $607 | $0 |
| Other | ||||
| Issuance Of Debt | $8,578,291 | $0 | $0 | - |
| End Cash Position | $6,322,397 | $5,240,477 | $4,222,143 | $34,078,525 |
| Beginning Cash Position | $5,240,477 | $4,222,143 | $34,078,525 | $42,594,258 |
| Effect Of Exchange Rate Changes | $80,476 | $-26,817 | $-7,181 | $0 |
| Changes In Cash | $1,001,445 | $1,045,150 | $-29,849,201 | $-8,515,733 |
| Net Issuance Payments Of Debt | $8,578,291 | $0 | $0 | - |
| Net Long Term Debt Issuance | $8,578,291 | $0 | $0 | - |
| Long Term Debt Issuance | $8,578,291 | $0 | $0 | - |
| Net Investment Purchase And Sale | $-16,626,227 | $7,877,767 | $-17,018,042 | $0 |
| Sale Of Investment | $21,307,120 | $26,613,169 | $0 | $0 |
| Purchase Of Investment | $-37,933,347 | $-18,735,402 | $-17,018,042 | $0 |
| Net PPE Purchase And Sale | $-8,721 | $-5,110 | $-15,774 | $-30,962 |
| Purchase Of PPE | $-8,721 | $-5,110 | $-15,774 | $-30,962 |
| Change In Working Capital | $-1,805,982 | $1,964,350 | $-477,636 | $274,845 |
| Change In Other Current Liabilities | $-251,541 | $79,225 | $-63,407 | $256,633 |
| Change In Other Current Assets | $-1,806,244 | $800,430 | $682,767 | $-489,427 |
| Change In Payables And Accrued Expense | $271,402 | $321,424 | $-463,297 | $973,714 |
| Change In Accrued Expense | $-1,228,825 | $284,728 | $369,573 | $-174,835 |
| Change In Payable | $1,500,228 | $36,696 | $-832,871 | $1,148,548 |
| Change In Account Payable | $1,500,228 | $36,696 | $-832,871 | $1,148,548 |
| Change In Prepaid Assets | $-19,600 | $763,271 | $-633,698 | $-466,075 |
| Stock Based Compensation | $1,154,910 | $969,067 | $846,259 | $826,644 |
| Unrealized Gain Loss On Investment Securities | $117,809 | $0 | $0 | - |
| Depreciation Amortization Depletion | $32,119 | $50,924 | $48,557 | $7,023 |
| Depreciation And Amortization | $32,119 | $50,924 | $48,557 | $7,023 |
| Depreciation | $32,119 | $50,924 | $48,557 | $7,023 |
| Pension And Employee Benefit Expense | $114,398 | $72,186 | $86,574 | $66,732 |
| Net Income From Continuing Operations | $-7,468,634 | $-10,193,863 | $-13,319,747 | $-9,696,629 |
| Net Foreign Currency Exchange Gain Loss | - | $0 | $0 | $36,613 |
| Proceeds From Stock Option Exercised | - | - | $0 | $0 |
| Other Non Cash Items | - | - | - | $36,613 |
Fetched: 2026-07-15